Khaireddin Riad, Wachtlin Joachim, Hopfenmüller Werner, Hoffmann Friedrich
Department of Ophthalmology, Charité University Medicine Berlin, Benjamin Franklin Campus, Hindenburgdamm 30, 12200 Berlin, Germany.
Graefes Arch Clin Exp Ophthalmol. 2003 Dec;241(12):1020-8. doi: 10.1007/s00417-003-0759-9. Epub 2003 Aug 29.
The purpose of this study is to determine the effectiveness of HLA typing in preventing corneal allograft rejection.
This retrospective single-center study analyzed 459 consecutive HLA-typed patients who underwent perforating keratoplasty (PKP) between 1983 and 2001. Grafts were postoperatively transparent after donor-recipient selection by HLA-A, -B and -DR typing. Patients were divided into a low- and a high-risk group based on their preoperative diagnosis.
The estimated 1-, 5- and 10-year graft survival (Kaplan-Meier) was 93, 88 and 67% in low-risk patients and 73, 43 and 38% in high-risk patients. We found a significant correlation between the number of HLA mismatches and the rate of allograft rejections: a donor-recipient match of two or more alleles in HLA-A, -B or -DR reduces the rejection rate by at least 10% in low-risk (10 years after PKP; P<0.04) and 40% in high-risk patients (3 years after PKP; P<0.0001). Especially HLA-B mismatches are important prognostic factors for both low- ( P<0.008) and high-risk patients ( P<0.003). Considering both HLA-B and -DR mismatches significantly reduces the rate of allograft rejection, particularly in high-risk patients ( P<0.0001). Matching on a split typing level offers no significant advantage over broad level matching.
Clinical results confirm theories developed to explain the function of the HLA (MHC) receptor. The closest possible donor-recipient match of HLA antigens based on broad level typing significantly reduces the rate of allograft rejection and thus improves the prognosis for long-term transparency of corneal grafts in both high- and low-risk patients.
本研究旨在确定 HLA 分型在预防角膜移植排斥反应中的有效性。
这项回顾性单中心研究分析了 1983 年至 2001 年间连续接受穿透性角膜移植术(PKP)的 459 例 HLA 分型患者。通过 HLA - A、- B 和 - DR 分型进行供体 - 受体选择后,术后移植片保持透明。根据术前诊断将患者分为低风险组和高风险组。
低风险患者估计的 1 年、5 年和 10 年移植片存活率(Kaplan - Meier 法)分别为 93%、88%和 67%,高风险患者分别为 73%、43%和 38%。我们发现 HLA 错配数与同种异体移植排斥率之间存在显著相关性:在 HLA - A、- B 或 - DR 中,供体 - 受体有两个或更多等位基因匹配可使低风险患者(PKP 术后 10 年;P<0.04)的排斥率至少降低 10%,高风险患者(PKP 术后 3 年;P<0.0001)降低 40%。特别是 HLA - B 错配对于低风险(P<0.008)和高风险患者(P<0.003)都是重要的预后因素。同时考虑 HLA - B 和 - DR 错配可显著降低同种异体移植排斥率,尤其是在高风险患者中(P<0.0001)。在细分分型水平上进行匹配与宽泛水平匹配相比没有显著优势。
临床结果证实了解释 HLA(MHC)受体功能的理论。基于宽泛水平分型实现供体 - 受体尽可能最接近的 HLA 抗原匹配可显著降低同种异体移植排斥率,从而改善高风险和低风险患者角膜移植片长期透明的预后。